CN117957213A - 包括经二取代的1,2,4-三嗪化合物的盐的可溶性药物组合物 - Google Patents

包括经二取代的1,2,4-三嗪化合物的盐的可溶性药物组合物 Download PDF

Info

Publication number
CN117957213A
CN117957213A CN202280051082.5A CN202280051082A CN117957213A CN 117957213 A CN117957213 A CN 117957213A CN 202280051082 A CN202280051082 A CN 202280051082A CN 117957213 A CN117957213 A CN 117957213A
Authority
CN
China
Prior art keywords
pharmaceutical composition
salt
compound
composition according
excipients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280051082.5A
Other languages
English (en)
Chinese (zh)
Inventor
罗伯特·麦基恩
小桥义则
尾崎文纪
大岛弘树
永田广臣
罗克·蒂伯特
伊丽莎白·瓦达斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Mineral Therapy Co
Original Assignee
Mitsubishi Tanabe Pharma Corp
Mineral Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp, Mineral Therapy Co filed Critical Mitsubishi Tanabe Pharma Corp
Publication of CN117957213A publication Critical patent/CN117957213A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280051082.5A 2021-07-20 2022-07-20 包括经二取代的1,2,4-三嗪化合物的盐的可溶性药物组合物 Pending CN117957213A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163223711P 2021-07-20 2021-07-20
US63/223,711 2021-07-20
PCT/IB2022/056709 WO2023002407A2 (en) 2021-07-20 2022-07-20 Soluble pharmaceutical compositions comprising salts of disubstituted 1, 2, 4-triazine compound

Publications (1)

Publication Number Publication Date
CN117957213A true CN117957213A (zh) 2024-04-30

Family

ID=84978780

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280051082.5A Pending CN117957213A (zh) 2021-07-20 2022-07-20 包括经二取代的1,2,4-三嗪化合物的盐的可溶性药物组合物

Country Status (6)

Country Link
US (1) US20240366616A1 (https=)
EP (1) EP4373812A4 (https=)
JP (1) JP2024525954A (https=)
KR (1) KR20240052937A (https=)
CN (1) CN117957213A (https=)
WO (1) WO2023002407A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230069126A (ko) * 2020-09-15 2023-05-18 미쓰비시 타나베 파마 코퍼레이션 트리아진 화합물의 염, 그 결정형 및 제조 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201212866D0 (en) * 2012-07-20 2012-09-05 Formac Pharmaceuticals Nv Dry granulates of mesoporous silica powders
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
KR20230069126A (ko) * 2020-09-15 2023-05-18 미쓰비시 타나베 파마 코퍼레이션 트리아진 화합물의 염, 그 결정형 및 제조 방법
JP2023546970A (ja) * 2020-10-26 2023-11-08 ミネラリス・セラピューティクス・インコーポレイテッド 高血圧のためのｃｙｐ１１ｂ２ベータヒドロキシラーゼ阻害剤

Also Published As

Publication number Publication date
EP4373812A4 (en) 2025-05-14
KR20240052937A (ko) 2024-04-23
EP4373812A2 (en) 2024-05-29
WO2023002407A3 (en) 2023-03-09
US20240366616A1 (en) 2024-11-07
WO2023002407A2 (en) 2023-01-26
JP2024525954A (ja) 2024-07-12

Similar Documents

Publication Publication Date Title
AU2017253367B2 (en) Orally disintegrating tablets
WO2022271600A1 (en) Stable varenicline dosage forms
JP6653116B2 (ja) オルメサルタンのプロドラッグ製剤
EP3102187B1 (en) Stable pharmaceutical compositions containing sitagliptin in the form of immediate release tablets
EP4424373B1 (en) Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
JP2010535754A (ja) 固形バルサルタン組成物
CN117957213A (zh) 包括经二取代的1,2,4-三嗪化合物的盐的可溶性药物组合物
EP3694493A1 (en) Tablet containing valsartan and sacubitril
IES20070122A2 (en) A process for the preparation of an orally administered unit dose tablet
WO1997039752A1 (en) Sertindole preparation and process for the production thereof
WO2017142438A1 (ru) Таблетки клозапина с замедленным высвобождением и способ их получения
HK40103672A (zh) 包括经二取代的1，2，4-三嗪化合物的盐的可溶性药物组合物
WO2019097090A1 (en) Pharmaceutical tablet composition comprising bilastine and magnesium aluminometasilicate
JP6765473B2 (ja) オルメサルタンのプロドラッグ製剤
EP3641735B1 (en) Pharmaceutical tablet composition comprising bilastine form 3 and a water-soluble filler
JP5802593B2 (ja) 結晶形安定化方法
WO2018079570A1 (ja) 安定な医薬組成物
JPWO2015199115A1 (ja) 経口投与用医薬組成物
EA033685B1 (ru) Фармацевтические лекарственные формы
WO2016118515A1 (en) Stable solid fingolimod dosage forms
AU2013223749A1 (en) Stable dosage forms of imatinib mesylate
EP2554164B1 (en) Pharmaceutical formulation based on ibuprofen and codeine having having improved stability
EP3407874B1 (en) Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
WO2025186786A1 (en) Oral pharmaceutical composition of pitavastatin and ezetimibe, method and uses thereof
RU2588840C1 (ru) Таблетки кветиапина с пролонгированным высвобождением и способ их получения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40103672

Country of ref document: HK